8-K: Teknova Reports Mixed Q2 2024 Results, Secures $15.4 Million in Funding

Teknova announced its second quarter 2024 financial results, showing a sequential revenue increase but a year-over-year decrease, while also securing $15.4 million in equity funding.

Summary

• Teknova's second quarter 2024 revenue was $9.6 million, a 3% increase compared to the first quarter of 2024, but a 17% decrease compared to the second quarter of 2023.
• When adjusted to exclude a large Clinical Solutions order from the second quarter of 2023, revenue increased by 9% year-over-year.
• The company's Lab Essentials revenue was flat year-over-year at $7.6 million, while Clinical Solutions revenue decreased by 57% to $1.6 million.
• Gross profit for the quarter was $2.8 million, with a gross margin of 29.2%, down from $5.1 million and 43.9% respectively in the same period last year.
• Operating expenses decreased to $7.9 million, compared to $12.1 million in the second quarter of 2023, excluding non-recurring charges.
• Net loss for the quarter was $5.4 million, or negative $0.13 per diluted share, compared to a net loss of $7.2 million, or negative $0.25 per diluted share, in the second quarter of 2023.
• Adjusted EBITDA was negative $2.6 million, compared to negative $2.3 million in the second quarter of 2023.
• Free cash flow was negative $3.0 million for the quarter, compared to negative $6.2 million in the same period last year.
• Teknova raised $15.4 million in equity capital in July 2024 through a private placement.
• The company reaffirmed its 2024 revenue guidance of $35-38 million and free cash outflow of less than $18 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has secured funding and launched new products, the year-over-year revenue decline and decreased gross margin are concerning. The reaffirmation of guidance provides some stability, but the overall financial performance is mixed.

Positives

• Sequential revenue increased by 3% compared to the previous quarter.
• The company successfully raised $15.4 million in equity capital, improving its liquidity.
• Operating expenses decreased by $2.0 million year-over-year, excluding non-recurring charges.
• Free cash outflow improved significantly year-over-year, from negative $6.2 million to negative $3.0 million.
• The number of clinical customers increased by 26% in the last six months.
• Two new product offerings were launched, providing customers with more customization options.

Negatives

• Total revenue decreased by 17% compared to the second quarter of 2023.
• Clinical Solutions revenue decreased by 57% compared to the same period last year.
• Gross profit decreased from $5.1 million to $2.8 million year-over-year.
• Gross margin decreased from 43.9% to 29.2% year-over-year.
• Adjusted EBITDA was negative $2.6 million, compared to negative $2.3 million in the second quarter of 2023.

Risks

• The company is facing a decrease in Clinical Solutions revenue, which significantly impacted overall revenue and gross profit.
• The company's gross margin has decreased due to lower Clinical Solutions revenue and increased overhead costs.
• Teknova is still experiencing a net loss and negative adjusted EBITDA.
• The company's future performance is subject to market recovery and biotech funding conditions.
• There is a risk of potential delays or pausing of customer orders.

Future Outlook

Teknova reaffirms its 2024 revenue guidance of $35-38 million, with approximately 5% growth in Lab Essentials and the remaining revenue from Clinical Solutions, and anticipates free cash outflow of less than $18 million for 2024.

Management Comments

• Stephen Gunstream, President and CEO, stated that the company delivered solid results in the first half of 2024 and is encouraged by the progress in onboarding new clinical customers.
• Matt Lowell, CFO, mentioned that the company is cautiously optimistic about market recovery and is maintaining its full-year outlook.
• Matt Lowell also stated that the $15.4 million equity capital raise provides sufficient liquidity to bridge the company through to cash flow positive.

Industry Context

Teknova operates in the life sciences industry, providing critical reagents for the development of therapies, vaccines, and diagnostics. The company's performance is influenced by biotech funding trends and the demand for its products in the clinical and research sectors. The launch of new offerings like Express-TekSM Production and RUO+ manufacturing grade indicates an effort to adapt to customer needs and market demands.

Comparison to Industry Standards

• Teknova's revenue decline of 17% year-over-year contrasts with some of its peers in the life sciences tools and reagents sector, which have shown more stable or positive growth. For example, companies like Thermo Fisher Scientific and Danaher have reported more consistent revenue growth, although they are much larger and more diversified.
• The decrease in gross margin from 43.9% to 29.2% is a significant drop and may indicate pricing pressures or increased costs compared to industry benchmarks. Companies like Bio-Rad Laboratories, which also operate in the reagents space, typically maintain higher gross margins.
• The negative adjusted EBITDA of $2.6 million suggests that Teknova is still in a growth phase and is not yet profitable, which is not uncommon for smaller companies in the biotech sector. However, it is important to compare this to similar-sized companies to assess its relative performance.
• The $15.4 million capital raise is a positive step for Teknova, but it also highlights the need for continued funding to reach profitability. This is a common challenge for companies in the biotech industry, where significant capital is required for research and development and scaling operations.

Stakeholder Impact

• Shareholders may be concerned about the year-over-year revenue decline and decreased gross margin, but the recent capital raise and reaffirmed guidance may provide some reassurance.
• Employees may be impacted by the company's cost-cutting measures, including reduced headcount.
• Customers may benefit from the new product offerings and increased customization options.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be monitoring the company's cash flow and debt levels.

Next Steps

• Teknova will attend the Sidoti Micro Cap Conference on August 15, 2024.
• The company will host a webcast and conference call on August 13, 2024, to discuss the results.
• Teknova will continue to focus on managing operating expenses and capital expenditures.
• The company will work towards achieving its 2024 revenue guidance and free cash outflow targets.

Key Dates

Keywords

Teknova, Financial Results, Second Quarter 2024, Revenue, Clinical Solutions, Lab Essentials, Equity Capital, Gross Profit, EBITDA, Free Cash Flow, Reagents, Biotech, Manufacturing